According to the SmPC, no dose adjustment is required for patients with mild to moderate renal or hepatic impairment, as pharmacokinetic changes across these populations are not clinically relevant, but use is not recommended in cases of severe renal or hepatic impairment due to limited experience
Research applications include receptor binding studies, pathway analysis, and experimental models evaluating peptide-mediated signaling processes
Plus, it is less painful than dermabrasion and chemical peels
The primary endpoint for the EMA was the percentage of patients achieving a SALT 10 at week 24, and the key secondary endpoint was improvement in the Patient's Global Impression of Change (PGI-C), defined as a rating of moderately improved or much improved at week 24 (PGI-C: a 7-point patient scale ranging from very much improved to very much worse).8 Baseline demographic and disease characteristics were balanced among treatment groups: 15% of patients were adolescents, 62% were women, 68% were White, and 46% had AT or AU
After missing a dose, many users report feeling impulsive, reactive, or out of sync emotionally
A spokesperson said: The World Anti-Doping Agency is looking into the allegations this is their role.